Skip to main content
Caplight Logo









TRIMTECH Therapeutics

TRIMTECH Therapeutics

Private
CambridgeHealthcare & Life Scienceshttps://trimtechtherapeutics.com/

Last Round

Seed

Jun 23, 2026

Total Funding Raised

$61M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

TRIMTECH Therapeutics is a biotechnology company that is developing a targeted protein degradation platform designed to address neurodegenerative diseases by degrading toxic protein aggregates.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

targeted protein degradationTPDsmall molecule degradersprotein aggregate degradationTRIMTACsneurodegenerative diseaseTRIM21 ligaseaggregate-selective degradersdrug discoveryAlzheimer's diseaseParkinson's diseaseHuntington's diseasepreclinical biotechinflammatory diseaseE3 ubiquitin ligase

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TRIMTECH Therapeutics Comparables

Compare TRIMTECH Therapeutics with similar companies based on industry and business-model similarity.

TRIMTECH Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Convergen Suzhou Pharmaceutical Co. Ltd.
88%
Plexium
79%
Amphista Therapeutics
79%

TRIMTECH Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJun 23, 2026
SeedMar 5, 2025

Key People

Founding team and executive leadership

Nicki Thompson

Chief Executive Officer

Executive Team

Julia Jones

Fractional CFO

Executive Team

TRIMTECH Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 22, 2026

    Monthly visitors increased 76% MoM.

  • Jul 28, 2026

    Monthly visitors increased 125% MoM, reaching 1.2K.

Recent news

Latest coverage and updates

  • receives_awardJul 16, 2026

    Trimtech Therapeutics Ltd. receives award o2h Kickstarter Award.

  • receives_financingJun 23, 2026

    TRIMTECH Therapeutics Limited receives financing of $14M in Seed 1.

  • is_developingJun 23, 2026

    Trimtech Therapeutics Ltd. is developing TRIMTAC and TRIMGLUE targeted protein degradation portfolio on Jun 23rd '26.

  • receives_financingJun 23, 2026

    Trimtech Therapeutics Ltd. received financing of $47M in Seed on Jun 23rd '26.

  • receives_financingJun 23, 2026

    Trimtech Therapeutics Ltd. received financing of $14M in Seed on Jun 23rd '26.

TRIMTECH Therapeutics Filings

Explore SEC and related filing metadata, where available.

TRIMTECH Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about TRIMTECH Therapeutics's valuation, stock price, and market status.

Is TRIMTECH Therapeutics a public or private company?

TRIMTECH Therapeutics is a private company.

What is the current stock price of TRIMTECH Therapeutics?

TRIMTECH Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is TRIMTECH Therapeutics worth (valuation)?

Valuation information for TRIMTECH Therapeutics is not publicly available.

Can I buy TRIMTECH Therapeutics stock?

TRIMTECH Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was TRIMTECH Therapeutics's last funding round?

TRIMTECH Therapeutics's most recent funding round was Seed on June 23, 2026.

Who are the main investors in TRIMTECH Therapeutics?

Key investors in TRIMTECH Therapeutics include BGF, Cambridge Innovation Capital, Johnson & Johnson Innovation - JJDC, Inc..

Will TRIMTECH Therapeutics IPO soon?

No public IPO plans have been announced for TRIMTECH Therapeutics.

How can I track TRIMTECH Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor TRIMTECH Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge
Employee Range18
Year Founded2023
Last FundingJun 23, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?